SEC 13F Intelligence

Managers / Q4 2023 · view latest →

Octagon Capital Advisors LP

CIK 0001839435 · 654 MADISON AVENUE, 21ST FLOOR, NEW YORK, NY, 10065 · 212-369-2829

Reported Value
$625M
Q4 2023
Positions
33
Filings on Record
23
2019–present window
Filed
Feb 14, 2024
original filing

Summary

Octagon Capital Advisors LP reported $625M in U.S.-listed holdings across 33 positions for Q4 2023.

The portfolio is heavily concentrated: APLSUSD alone accounts for 26.9% of reported value.

Compared with Q3 2023, the fund opened 10 new positions and exited 14.

Portfolio Metrics

Turnover
+22.4%
vs prior filed quarter
Top-10 Concentration
+76.6%
share of reported value
Largest Position
+26.9%
Apellis Pharmaceuticals
New / Exited
10 / 14
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’20: $288MQ4 ’20Q1 ’21: $265MQ2 ’21: $483MQ3 ’21: $406MQ3 ’21Q4 ’21: $514MQ1 ’22: $463MQ2 ’22: $375MQ2 ’22Q3 ’22: $579MQ4 ’22: $642MQ1 ’23: $695MQ1 ’23Q2 ’23: $719MQ3 ’23: $651MQ4 ’23: $625MQ4 ’23Q1 ’24: $834MQ2 ’24: $636MQ3 ’24: $643MQ3 ’24Q4 ’24: $608MQ1 ’25: $517MQ2 ’25: $456MQ2 ’25Q3 ’25: $660MQ4 ’25: $824MQ1 ’26: $904MQ1 ’26filingsflow.com

Portfolio Composition

By security type
Common Stock: 77.5%ADR: 12.9%Other: 9.6%
  • Common Stock · 77.5% · $484M
  • ADR · 12.9% · $80M
  • Other · 9.6% · $60M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2023 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
GPCRSTRUCTURE THERAPEUTICS INCNEW+414.0K414.0K+$17M$17M
CYTKCYTOKINETICS INCNEW+116.0K116.0K+$10M$10M
RAPT THERAPEUTICS INCNEW+292.0K292.0K+$7M$7M
GRACELL BIOTECHNOLOGIES INCNEW+596.6K596.6K+$6M$6M
VERUEURVERU INCNEW+3.80M3.80M+$3M$3M
ANABANAPTYSBIO INCNEW+120.0K120.0K+$3M$3M
NUVBNUVATION BIO INCNEW+1.00M1.00M+$2M$2M
MIRMMIRUM PHARMACEUTICALS INCNEW+25.0K25.0K+$738,000$738,000

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2023

33 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1APLSUSDAPELLIS PHARMACEUTICALS INChistory →COM26.88%$168M2.81M
2CYMABAY THERAPEUTICS INCCOM10.10%$63M2.67M
3VRNAVERONA PHARMA PLChistory →SPONSORED ADS7.54%$47M2.37M
4IM8NINSMED INChistory →COM PAR $.016.37%$40M1.28M
5RCUSARCUS BIOSCIENCES INChistory →COM5.71%$36M1.87M
6BBIOBRIDGEBIO PHARMA INChistory →COM4.57%$29M706.8K
7TCE2CELLDEX THERAPEUTICS INC NEWhistory →COM NEW4.49%$28M707.5K
8ROIVANT SCIENCES LTDSHS4.48%$28M2.49M
9NVLSEURALPINE IMMUNE SCIENCES INChistory →COM3.79%$24M1.24M
10GPCRSTRUCTURE THERAPEUTICS INChistory →SPONSORED ADS2.70%$17M414.0K
11260CENTESSA PHARMACEUTICALS PLChistory →SPONSORED ADS2.62%$16M2.06M
12ANTXAN2 THERAPEUTICS INChistory →COM2.18%$14M664.6K
13VRDNVIRIDIAN THERAPEUTICS INChistory →COM2.16%$14M620.0K
14IMVTIMMUNOVANT INChistory →COM1.84%$12M273.3K
15DYNDYNE THERAPEUTICS INChistory →COM1.69%$11M792.9K
16CYTKCYTOKINETICS INChistory →COM NEW1.55%$10M116.0K
17ANNXANNEXON INChistory →COM1.49%$9M2.05M
18AEROVATE THERAPEUTICS INCCOM1.46%$9M403.7K
19GOSSGOSSAMER BIO INChistory →COM1.34%$8M9.19M
20RAPT THERAPEUTICS INCCOM1.16%$7M292.0K
21GLYCEURGLYCOMIMETICS INChistory →COM1.13%$7M3.00M
22GRACELL BIOTECHNOLOGIES INCSPONSORED ADS0.96%$6M596.6K
23DNTHDIANTHUS THERAPEUTICS INCCOM0.92%$6M554.0K
24RENEO PHARMACEUTICALS INCCOM0.58%$4M2.25M
25JASPER THERAPEUTICS INCCOM0.56%$4M4.47M
26VERUEURVERU INCCOM0.44%$3M3.80M
27ANABANAPTYSBIO INCCOM0.41%$3M120.0K
28INOZYME PHARMA INCCOM0.27%$2M400.0K
29NUVBNUVATION BIO INCCOM CL A0.24%$2M1.00M
30XILIO THERAPEUTICS INCCOM0.16%$981,7501.78M
31MIRMMIRUM PHARMACEUTICALS INCCOM0.12%$738,00025.0K
32PHATPHATHOM PHARMACEUTICALS INCCOM0.07%$456,50050.0K
33ACRSACLARIS THERAPEUTICS INCCOM0.02%$105,000100.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$904M29May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$824M27Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$660M27Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$456M30Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$517M35May 16, 2025RESTATEMENTchanges · EDGAR ↗
Q4 2024$608M33Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$643M42Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$636M47Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$834M57May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$625M33Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$651M40Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$719M41Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$695M36May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$642M32Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$579M35Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$375M20Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$463M24May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$514M28Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$406M30Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$483M34Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$265M28May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$288M31Feb 16, 202113F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.